Itch Drug Volixibat Improves Sleep in Liver Disease

Adults with primary sclerosing cholangitis and severe itch saw better sleep on the investigational drug in a phase 2b trial.

Updated on Nov. 5, 2026 in Sleep Disorders

Soft dawn light falls across a rumpled bed and a glass of water on a windowsill in a quiet bedroom, evoking restful sleep.
Adults with a rare liver disease who took the investigational drug volixibat reported better sleep than those on placebo in a phase 2b trial presented in Denver. AI Illustration. Upload story photo >

Volixibat, an investigational drug, improved sleep compared with placebo in adults with primary sclerosing cholangitis and cholestatic itch in the phase 2b VISTAS trial. Pruritus responders also reported greater improvements in fatigue and sleep than nonresponders, a finding presented at The Liver Meeting 2026 in Denver, Colorado.

Why it matters

Itch in liver disease is often severe and can disrupt rest and daily energy, so a measurable sleep benefit adds a patient-centered outcome beyond itch scores alone. The data suggest that relieving itch may carry downstream benefits for sleep, though the drug remains investigational and the findings come from a single trial.

This phase 2b randomized, placebo-controlled trial enrolled 111 adults with primary sclerosing cholangitis and moderate to severe pruritus, with sleep and fatigue assessed through Week 28 using validated PROMIS measures. The sleep improvement over placebo was statistically significant, while the fatigue difference was not.

The players

Mirum Pharmaceuticals

A biopharmaceutical company developing treatments for rare liver diseases, including the investigational bile acid transporter inhibitor volixibat.

Christopher Bowlus

A hepatology researcher at the University of California, Davis, who presented the VISTAS sleep and fatigue analysis.

U.S. Food and Drug Administration

The federal agency that regulates drug approval and granted volixibat Breakthrough Therapy and Orphan Drug designations.

The details

Volixibat is an ileal bile acid transporter inhibitor, a class of drug that works in the intestine to reduce how much bile acid is reabsorbed back into the body. Investigators linked the sleep and fatigue gains to itch relief by comparing pruritus responders, defined as those with at least a 2-point drop in itch score, against nonresponders regardless of treatment arm. Responders showed a mean sleep change of -7.48 versus 0.18 for nonresponders, and a fatigue change of -6.25 versus -0.34. The drug's most common side effect was diarrhea, reported by 40.3% of volixibat-treated participants compared with 8.6% on placebo.

Timeline

  1. August 2026: The FDA granted volixibat Breakthrough Therapy and Orphan Drug designations.

  2. November 5, 2026: Christopher Bowlus presented the VISTAS sleep and fatigue analysis at The Liver Meeting 2026.

  3. First half of 2027: Mirum Pharmaceuticals plans to discuss a potential new drug application with the FDA.

Health Landscape

Cholestatic itch remains one of the hardest symptoms to treat in chronic liver disease, and current options are limited for many patients. Expanding the evaluation of drugs like volixibat to include sleep and fatigue outcomes reflects a broader shift toward measuring how these conditions affect daily life.

If you live with a chronic liver condition that causes persistent itch, this research suggests that treating itch may also improve sleep and energy, which is worth raising with your hepatologist. Because volixibat is still investigational and carries a notable risk of diarrhea, discuss any new treatment options with your physician before making decisions about your care.

The takeaway

Better itch control in liver disease may bring meaningful gains in sleep and fatigue, a benefit worth tracking as new treatments advance. Talk with your doctor about how itch is affecting your rest and daily energy, and ask whether any current options or upcoming trials might be appropriate for you.

What happens next

Mirum Pharmaceuticals plans further discussions with the FDA and a potential new drug application submission in the first half of 2027.

Further reading

For more on how sleep problems are studied and treated, explore our Sleep Disorders coverage.